Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ultragenyx Pharmaceutical Inc
ClinicalTrials.gov Identifier:
NCT01517880
First received: January 17, 2012
Last updated: January 15, 2014
Last verified: January 2014

January 17, 2012
January 15, 2014
May 2012
November 2013   (final data collection date for primary outcome measure)
Evaluate the effect of SA-ER treatment on muscle sialylation, strength, and function in patients with HIBM. [ Time Frame: Baseline, Week 24, and Week 48 ] [ Designated as safety issue: No ]
To evaluate the effect of SA-ER treatment on improvement of biochemical measures of sialylation and pathology in muscle. On mobility, strength, and function using a series of quantitative and physical performance measures and quality of life using patient-reported outcome measures.
Change from baseline in total SA bound to muscle proteins and lipids and free SA will be determined on muscle biopsies taken at 24 and 48 weeks. [ Time Frame: The same muscles will be evaluated by biopsy at Baseline, 24, and 48 weeks for each subject. ] [ Designated as safety issue: No ]
The choice of muscle will depend on the MRI evaluation at Screening, and the same muscles will be evaluated at Baseline, 24, and 48 weeks for each subject. Sialylation of polysialylated neural cell adhesion molecule (PSA-NCAM) will also be determined in these biopsies.
Complete list of historical versions of study NCT01517880 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

GNE myopathy or hereditary inclusion body myopathy (HIBM) is a severe progressive metabolic myopathy caused by a defect in the biosynthetic pathway for sialic acid (SA).

GNE myopathy or hereditary inclusion body myopathy (HIBM) is a severe progressive metabolic myopathy caused by a defect in the biosynthetic pathway for sialic acid (SA). Substrate replacement therapy is a potential therapeutic strategy based on the success of replacing missing SA and reducing muscle disease in a relevant mouse model of the human disease (Malicdan et al., 2009). Successful use of SA replacement therapy in humans is believed to depend upon providing steady long-term exposure to the compound in an extended release form (such as Sialic Acid-Extended Release [SA-ER]), given SA's short half-life. Following a Phase 1 study to establish the pharmacokinetics (PK) for SA-ER, Ultragenyx is conducting this study to assess the dose and potential pharmacodynamic effect of restoring sialylation of muscle by treatment with SA-ER at two dose levels as compared to placebo when administered over two 24 week periods of time. The study will also evaluate safety, as well as the effect of SA-ER on clinical measures of muscle strength, mobility, function and self-reported disability and quality of life. Effects on muscle volume/mass and function and on serum biomarkers will be evaluated as exploratory measures. These data should allow the selection of a dose and the appropriate design for a Phase 3 clinical study.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • GNE Myopathy
  • Hereditary Inclusion Body Myopathy
  • Drug: Sialic Acid Extended Release (SA-ER)
    SA-ER will be administered in doses of 3000mg per day or 6000mg per day
  • Drug: Placebo
    Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
  • Experimental: 6,000 mg SA-ER
    Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
    Intervention: Drug: Sialic Acid Extended Release (SA-ER)
  • Placebo Comparator: Placebo
    Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).
    Intervention: Drug: Placebo
  • Experimental: 3,000 mg SA-ER
    Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
    Intervention: Drug: Sialic Acid Extended Release (SA-ER)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
November 2013
November 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Must be between 18 and 65 years of age, inclusive.
  2. Must be willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
  3. Must have a documented diagnosis of GNE myopathy, HIBM, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene encoding the GNE/MNK enzyme. Genotyping will not be conducted in this protocol.
  4. Must be able to walk 20 meters independently (may use orthotics and assistive devices).
  5. Must be able to provide reproducible force in bilateral elbow flexors and knee extensors during hand-held dynamometry testing (unilateral between test variability of < 15% for both muscle groups).
  6. Must be willing and able to comply with all study procedures including fine needle muscle biopsies of the upper (e.g., triceps brachii or posterior deltoid) and lower (e.g., biceps femoris or vastus lateralis) extremities at Baseline and 24 and 48 weeks.
  7. Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
  8. Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause for at least two years, or have had tubal ligation at least one year prior to Screening, or who have had total hysterectomy.

Exclusion Criteria:

  1. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
  2. Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  3. Ingestion of N-acetyl-D-mannosamine (ManNAc), SA, or related metabolites; intravenous immune globulin (IVIG); or anything that can be metabolized to produce SA in the body for the prior 60 days.
  4. Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe participation in the study.
  5. Has had any hypersensitivity to SA or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects.
  6. Has a concurrent disease or condition that, in the view of the principal investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety.
  7. Has serum transaminase (i.e., alanine aminotransferase [ALT], aspartate aminotransferase [AST], or gamma-glutamyl transpeptidase [GGT]) levels greater than three times the upper limit of normal or serum creatinine of greater than 2.0 mg/dL.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Israel
 
NCT01517880
UX001-CL201
Yes
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc
Not Provided
Principal Investigator: Alan Pestronk, MD Washington University School of Medicine
Principal Investigator: Perry Shieh, MD University of California, Los Angeles
Principal Investigator: Yoseph Caraco, MD Hadassah University Hospital
Principal Investigator: Heather Lau, MD New York University School of Medicine
Ultragenyx Pharmaceutical Inc
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP